title: Metachromatic leukodystrophy: molecular genetics and an animal model.
abstract: Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder caused by the deficiency of arylsulphatase A (ASA; EC 3.1.6.8). Deficiency of this enzyme causes intralysosomal storage of the sphingolipid cerebroside sulphate. This lipid is abundant in myelin and it may thus not be surprising that storage mainly affects oligodendrocytes. Patients suffer from a progressive demyelination causing various neurological symptoms. The disease is fatal and treatment is not available. The human ASA gene has been cloned and more than 40 mutations have been analysed that cause metachromatic leukodystrophy. Few of these alleles are frequent among patients, whereas most mutant alleles have only been found in single families. Since MLD has only been described in humans and no naturally occurring animal model has been described, ASA-deficient mice have been generated by homologous recombination. The ASA knockout mice are unable to degrade sulphatide and store the lipid intralysosomally. The pattern of lipid storage in neuronal and non-neuronal tissues resembles that described for patients. In the nervous system, lipid storage is found in oligodendrocytes, astrocytes and some neurons. Animals display an astrogliosis and a decreased average axonal diameter. Purkinje cells and Bergmann glia of the cerebellum are morphologically aberrant. Demyelination is seen in the acoustic ganglion and occurs between the ages of 6 and 12 months. The animals are deaf at this age and display various neuromotor abnormalities. However, compared to humans the mice have a surprisingly mild phenotype, since they have a normal life span and do not develop widespread demyelination. ASA-deficient mice have been transplanted with bone marrow, which was transduced with a retroviral vector expressing arylsulphatase A. The majority of transplanted animals display sustained expression of arylsulphatase A from the retroviral construct up to 5 months after transplantation. However, preliminary data suggest that this therapeutic approach does not reduce storage material.
authors.affiliation: Biochemisches Institut der Christian-Albrechts-Universität zu Kiel, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Gieselmann
authors.forename: U
authors.initials: U
authors.lastname: Matzner
authors.forename: B
authors.initials: B
authors.lastname: Hess
authors.forename: R
authors.initials: R
authors.lastname: Lüllmann-Rauch
authors.forename: R
authors.initials: R
authors.lastname: Coenen
authors.forename: D
authors.initials: D
authors.lastname: Hartmann
authors.forename: R
authors.initials: R
authors.lastname: D'Hooge
authors.forename: P
authors.initials: P
authors.lastname: DeDeyn
authors.forename: G
authors.initials: G
authors.lastname: Nagels
mesh_terms: D000818:Animals; D002553:Cerebroside-Sulfatase / Q000172:deficiency / Q000235:genetics; D004195:Disease Models, Animal; D006801:Humans; D007966:Leukodystrophy, Metachromatic / Q000235:genetics*; D051379:Mice; D008817:Mice, Mutant Strains
chemical_list: D002553:Cerebroside-Sulfatase